Mersana Total Liab vs Net Tangible Assets Analysis

MRSN Stock

USD 6.95 0.12 1.76%

Mersana Therapeutics financial indicator trend analysis is infinitely more than just investigating Mersana Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mersana Therapeutics is a good investment. Please check the relationship between Mersana Therapeutics Total Liab and its Net Tangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

Total Liab vs Net Tangible Assets

Total Liab vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mersana Therapeutics Total Liab account and Net Tangible Assets. At this time, the significance of the direction appears to have very week relationship.

The correlation between Mersana Therapeutics' Total Liab and Net Tangible Assets is 0.21. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Mersana Therapeutics, assuming nothing else is changed. The correlation between historical values of Mersana Therapeutics' Total Liab and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Mersana Therapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Total Liab i.e., Mersana Therapeutics' Total Liab and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.21

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Mersana Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mersana Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.As of the 30th of July 2025, Tax Provision is likely to grow to about 438.9 K, while Selling General Administrative is likely to drop about 30 M.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	927K	1.5M	1.6M	1.1M
Interest Income	2.9M	11.0M	8.4M	8.9M

Depreciation And Amortization Interest Income

Mersana Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab
Total Assets		0.9	0.77	0.78	0.54	0.84	0.93	0.34	-0.81	-0.71	0.8	0.87	0.9	0.19	0.46	1.0	0.53	0.86	0.76	0.42	0.85	-0.77	0.69	0.83	0.63	-0.46
Other Current Liab	0.9		0.88	0.59	0.59	0.71	0.91	0.41	-0.6	-0.77	0.88	0.7	0.83	0.24	0.18	0.88	0.66	0.85	0.8	0.46	0.84	-0.79	0.84	0.86	0.71	-0.51
Total Current Liabilities	0.77	0.88		0.38	0.67	0.54	0.69	0.77	-0.48	-0.77	0.81	0.57	0.72	0.45	0.02	0.76	0.56	0.75	0.75	0.47	0.76	-0.78	0.68	0.8	0.76	-0.5
Total Stockholder Equity	0.78	0.59	0.38		-0.03	0.91	0.76	-0.04	-0.79	-0.28	0.68	0.77	0.83	0.33	0.77	0.78	0.21	0.73	0.43	-0.18	0.6	-0.67	0.56	0.54	0.03	-0.22
Other Liab	0.54	0.59	0.67	-0.03		0.29	0.44	0.49	-0.23	-0.89	0.28	0.35	0.36	-0.15	-0.22	0.53	0.37	0.53	0.77	0.72	0.7	-0.42	0.18	0.72	0.81	-0.33
Net Tangible Assets	0.84	0.71	0.54	0.91	0.29		0.85	0.05	-0.83	-0.61	0.7	0.86	0.89	0.32	0.67	0.86	0.13	0.91	0.71	-0.03	0.85	-0.8	0.56	0.79	0.21	-0.36
Property Plant And Equipment Net	0.93	0.91	0.69	0.76	0.44	0.85		0.14	-0.82	-0.72	0.83	0.89	0.88	0.2	0.46	0.93	0.43	0.89	0.79	0.34	0.87	-0.8	0.8	0.85	0.54	-0.56
Current Deferred Revenue	0.34	0.41	0.77	-0.04	0.49	0.05	0.14		-0.12	-0.4	0.42	0.15	0.31	0.5	-0.23	0.33	0.33	0.24	0.31	0.36	0.29	-0.38	0.26	0.35	0.59	-0.22
Net Debt	-0.81	-0.6	-0.48	-0.79	-0.23	-0.83	-0.82	-0.12		0.5	-0.61	-0.99	-0.74	-0.32	-0.77	-0.84	-0.07	-0.75	-0.6	-0.18	-0.7	0.7	-0.47	-0.66	-0.33	0.59
Retained Earnings	-0.71	-0.77	-0.77	-0.28	-0.89	-0.61	-0.72	-0.4	0.5		-0.55	-0.63	-0.61	-0.11	-0.03	-0.71	-0.26	-0.81	-0.94	-0.51	-0.93	0.73	-0.45	-0.92	-0.7	0.53
Accounts Payable	0.8	0.88	0.81	0.68	0.28	0.7	0.83	0.42	-0.61	-0.55		0.67	0.82	0.59	0.3	0.78	0.51	0.74	0.57	0.1	0.73	-0.87	0.85	0.67	0.42	-0.57
Cash	0.87	0.7	0.57	0.77	0.35	0.86	0.89	0.15	-0.99	-0.63	0.67		0.79	0.29	0.68	0.89	0.14	0.82	0.7	0.25	0.8	-0.77	0.55	0.76	0.42	-0.62
Non Current Assets Total	0.9	0.83	0.72	0.83	0.36	0.89	0.88	0.31	-0.74	-0.61	0.82	0.79		0.36	0.44	0.9	0.33	0.83	0.65	0.12	0.82	-0.75	0.77	0.76	0.39	-0.25
Non Currrent Assets Other	0.19	0.24	0.45	0.33	-0.15	0.32	0.2	0.5	-0.32	-0.11	0.59	0.29	0.36		0.34	0.2	-0.1	0.27	0.06	-0.45	0.25	-0.58	0.3	0.16	-0.14	-0.39
Other Assets	0.46	0.18	0.02	0.77	-0.22	0.67	0.46	-0.23	-0.77	-0.03	0.3	0.68	0.44	0.34		0.49	-0.09	0.41	0.16	-0.31	0.31	-0.39	0.07	0.24	-0.22	-0.27
Cash And Short Term Investments	1.0	0.88	0.76	0.78	0.53	0.86	0.93	0.33	-0.84	-0.71	0.78	0.89	0.9	0.2	0.49		0.48	0.87	0.77	0.41	0.85	-0.78	0.66	0.84	0.62	-0.47
Net Receivables	0.53	0.66	0.56	0.21	0.37	0.13	0.43	0.33	-0.07	-0.26	0.51	0.14	0.33	-0.1	-0.09	0.48		0.28	0.3	0.55	0.25	-0.23	0.49	0.33	0.64	-0.16
Common Stock Total Equity	0.86	0.85	0.75	0.73	0.53	0.91	0.89	0.24	-0.75	-0.81	0.74	0.82	0.83	0.27	0.41	0.87	0.28		0.92	0.24	0.93	-0.89	0.64	0.96	0.49	-0.52
Common Stock Shares Outstanding	0.76	0.8	0.75	0.43	0.77	0.71	0.79	0.31	-0.6	-0.94	0.57	0.7	0.65	0.06	0.16	0.77	0.3	0.92		0.51	0.9	-0.76	0.53	0.99	0.69	-0.53
Non Current Liabilities Total	0.42	0.46	0.47	-0.18	0.72	-0.03	0.34	0.36	-0.18	-0.51	0.1	0.25	0.12	-0.45	-0.31	0.41	0.55	0.24	0.51		0.3	-0.07	0.24	0.44	0.93	-0.3
Capital Surpluse	0.85	0.84	0.76	0.6	0.7	0.85	0.87	0.29	-0.7	-0.93	0.73	0.8	0.82	0.25	0.31	0.85	0.25	0.93	0.9	0.3		-0.86	0.58	0.94	0.55	-0.54
Inventory	-0.77	-0.79	-0.78	-0.67	-0.42	-0.8	-0.8	-0.38	0.7	0.73	-0.87	-0.77	-0.75	-0.58	-0.39	-0.78	-0.23	-0.89	-0.76	-0.07	-0.86		-0.62	-0.82	-0.38	0.71
Other Current Assets	0.69	0.84	0.68	0.56	0.18	0.56	0.8	0.26	-0.47	-0.45	0.85	0.55	0.77	0.3	0.07	0.66	0.49	0.64	0.53	0.24	0.58	-0.62		0.61	0.46	-0.34
Other Stockholder Equity	0.83	0.86	0.8	0.54	0.72	0.79	0.85	0.35	-0.66	-0.92	0.67	0.76	0.76	0.16	0.24	0.84	0.33	0.96	0.99	0.44	0.94	-0.82	0.61		0.66	-0.52
Total Liab	0.63	0.71	0.76	0.03	0.81	0.21	0.54	0.59	-0.33	-0.7	0.42	0.42	0.39	-0.14	-0.22	0.62	0.64	0.49	0.69	0.93	0.55	-0.38	0.46	0.66		-0.43
Deferred Long Term Liab	-0.46	-0.51	-0.5	-0.22	-0.33	-0.36	-0.56	-0.22	0.59	0.53	-0.57	-0.62	-0.25	-0.39	-0.27	-0.47	-0.16	-0.52	-0.53	-0.3	-0.54	0.71	-0.34	-0.52	-0.43

Click cells to compare fundamentals

Mersana Therapeutics Account Relationship Matchups

Mersana Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	273.4M	206.1M	334.3M	226.1M	144.7M	178.3M
Other Current Liab	16.2M	29.0M	44.2M	22.7M	19.6M	18.2M
Total Current Liabilities	30.0M	47.5M	91.5M	63.6M	62.5M	50.6M
Total Stockholder Equity	228.1M	121.7M	92.1M	36.9M	(9.5M)	(9.0M)
Net Tangible Assets	78.3M	228.1M	155.5M	92.1M	105.9M	73.5M
Property Plant And Equipment Net	12.7M	14.9M	14.5M	11.5M	6.8M	8.1M
Current Deferred Revenue	4.0M	3.9M	30.6M	28.1M	22.2M	21.0M
Net Debt	(238.5M)	(139.8M)	(92.6M)	(140.7M)	(79.2M)	(83.1M)
Retained Earnings	(280.4M)	(450.5M)	(654.7M)	(826.4M)	(895.6M)	(850.8M)
Accounts Payable	8.3M	12.3M	14.0M	7.3M	4.3M	7.9M
Cash	255.1M	177.9M	128.9M	174.6M	107.8M	121.5M
Non Current Assets Total	14.8M	17.2M	15.1M	12.0M	7.8M	10.9M
Non Currrent Assets Other	2.2M	1.9M	661K	478K	978K	1.5M
Other Assets	1.5M	13.1M	2.4M	661K	760.2K	722.1K
Cash And Short Term Investments	255.1M	177.9M	280.7M	209.1M	134.6M	159.9M
Common Stock Shares Outstanding	61.5M	70.6M	93.7M	116.1M	122.5M	64.7M
Liabilities And Stockholders Equity	273.4M	206.1M	334.3M	226.1M	144.7M	178.3M
Non Current Liabilities Total	15.3M	36.8M	150.8M	125.5M	91.7M	69.6M
Capital Surpluse	173.0M	270.7M	508.5M	572.2M	658.0M	690.9M
Other Current Assets	3.5M	21.9M	17.0M	9.9M	2.3M	2.2M
Other Stockholder Equity	508.5M	572.2M	746.9M	863.2M	886.0M	462.3M
Total Liab	45.3M	84.4M	242.3M	189.2M	154.2M	120.2M
Property Plant And Equipment Gross	12.7M	22.5M	22.2M	20.6M	17.1M	11.9M
Total Current Assets	258.6M	188.9M	319.2M	214.1M	136.9M	167.4M
Accumulated Other Comprehensive Income	25K	0.0	(152K)	11K	10K	10.5K
Property Plant Equipment	4.8M	1.7M	14.9M	14.5M	16.6M	17.5M
Non Current Liabilities Other	10.3M	974K	203K	55K	8K	7.6K
Long Term Debt	5.0M	24.6M	24.9M	23.1M	11.0M	14.6M
Retained Earnings Total Equity	(164.2M)	(192.4M)	(280.4M)	(450.5M)	(405.4M)	(385.2M)
Net Invested Capital	233.1M	146.4M	117.0M	62.1M	13.9M	13.2M
Net Working Capital	228.6M	141.4M	227.7M	150.4M	74.4M	136.2M
Short Long Term Debt Total	16.6M	38.2M	36.3M	33.8M	28.6M	29.6M

When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:

How To Invest In Mersana

Details

Is Mersana Stock a good investment?

Details

What is Mersana Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(14.75)

Revenue Per Share

6.895

Quarterly Revenue Growth

(0.70)

Return On Assets

(0.31)

Return On Equity

(5.05)

The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Mersana Total Liab vs Net Tangible Assets Analysis

Total Liab vs Net Tangible Assets

Total Liab vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Total Liab

Net Tangible Assets

Mersana Therapeutics fundamental ratios Correlations

Mersana Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mersana Therapeutics fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Other Stockholder Equity	+ 0.96	Common Stock Total Equity
Other Stockholder Equity	+ 0.94	Capital Surpluse
Property Plant And Equipment Net	+ 0.93	Total Assets
Cash And Short Term Investments	+ 0.93	Property Plant And Equipment Net

Cash	- 0.99	Net Debt
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.92	Retained Earnings
Inventory	- 0.89	Common Stock Total Equity
Retained Earnings	- 0.89	Other Liab